2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-146667
    POP-IN-1 2743432-99-5 98%
    POP-IN-1 (Compound 12h) is a potent inhibitor of POP with an Ki of 0.009 μM. POP-IN-1 has the potential for the research of neurodegenerative diseases and cancer progression.
    POP-IN-1
  • HY-146668
    AChE/BChE-IN-8 2421120-96-7 98%
    AChE/BChE-IN-8 (Compound 5a) is an uncompetitive AChE and mixed BChE inhibitor with Ki values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE (EeAChE) and equine BChE (eqBChE), respectively. AChE/BChE-IN-8 can cross the BBB and has low cytotoxicity.
    AChE/BChE-IN-8
  • HY-146669
    BChE-IN-6 2421121-10-8 98%
    BChE-IN-6 (compound 12) is a potent BChE inhibitor, with a Ki of 0.182 μM. BChE-IN-6 shows chelating capacity on Zn2+. BChE-IN-6 can be used for Alzheimer’s disease (AD) research.
    BChE-IN-6
  • HY-146677
    5-HT6R/MAO-B modulator 1 2986222-45-9 98%
    5-HT6R/MAO-B modulator 1 (compound 48) is an antagonist of 5-HT6R at Gs signaling and an irreversible MAO-B inhibitor. 5-HT6R/MAO-B modulator 1 exhibits glioprotective properties. 5-HT6R/MAO-B modulator 1 can reverse Scopolamine-induced memory deficits. 5-HT6R/MAO-B modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    5-HT6R/MAO-B modulator 1
  • HY-146686
    BuChE-IN-3 2499488-78-5 98%
    BuChE-IN-3 (Compound C4) is a potent inhibitor of BuChE with an IC50 of 8.3 nM. BuChE-IN-3 exhibits mild antioxidant capacity, nontoxicity, lipophilicity and neuroprotective activity.
    BuChE-IN-3
  • HY-146687
    BuChE-IN-4 2499490-52-5 98%
    BuChE-IN-4 (Compound C6) is a potent inhibitor of BuChE with an IC50 of 7.7 nM. BuChE-IN-4 exhibits mild antioxidant capacity, nontoxicity, lipophilicity and neuroprotective activity.
    BuChE-IN-4
  • HY-146691
    hMAO-B-IN-2 2454459-87-9 98%
    hMAO-B-IN-2 (compound 6j) is an orally active, potent, selective and BBB penetrated and competitive reversible hMAO-B inhibitor, with an IC50 of 4 nM. hMAO-B-IN-2 shows low toxicity and good neuroprotective effects in SH-SY5Y cell. hMAO-B-IN-2 can be used for alzheimer’s disease research. hMAO-B-IN-2 is a click chemistry reagent, itcontains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    hMAO-B-IN-2
  • HY-146758
    RIPK1-IN-14 2919964-79-5 98%
    RIPK1-IN-14 (Compound 41) is a potent inhibitor of RIPK1 with an IC50 value of 92 nM. RIPK1-IN-14 shows a significant anti-necroptotic effect in a necroptosis model in U937 cells.
    RIPK1-IN-14
  • HY-146762
    MAO-B-IN-7 2851012-65-0 98%
    MAO-B-IN-7 is a potent and blood-brain barrier permeable MAO-B and AChE inhibitor with IC50s of 41 nM, 87 nM and 0.3 μM for human AChE, electric eel AChE and MAO-B, respectively. MAO-B-IN-7 can effectively alleviate oxidative stress and neuroinflammatory damage.
    MAO-B-IN-7
  • HY-146959
    K203 955034-69-2 98%
    K203 is a potent reactivator of tabun-inhibited AChE. K203 is a crucial antidote used for the organophosphate intoxication.
    K203
  • HY-147225
    TSPO Ligand-Linker Conjugates 1 98%
    TSPO Ligand-Linker Conjugates 1 contains a ligand for translocator protein (TSPO) and a linker, which is used for the synthesis of mitochondria-targeting autophagy-targeting chimera (AUTAC). AUTAC can bind the TSPO on the outer mitochondrial membrane (OMM) of mitochondria and degrades impaired mitochondria and proteins via mitophagy, and improves mitochondrial activity. TSPO Ligand-Linker Conjugates 1 can be used in mitochondrial dysfunction related research, including neurodegenerative diseases, cancer, and diabetes.
    TSPO Ligand-Linker Conjugates 1
  • HY-147234
    Sirtuin modulator 2 667910-69-2 99.22%
    Sirtuin modulator 2 (Compound 132) is a sirtuin modulator with an ED50 equal or less than 50 μM.
    Sirtuin modulator 2
  • HY-147285
    PI3K/mTOR Inhibitor-9 1392421-71-4 98%
    PI3K/mTOR Inhibitor-9 (Compound 1) is a potent mTOR and PI3K inhibitor with IC50 values of 38 nM, 6.6 μM, 6.6 μM and 0.8 μM against mTOR (phospho-S6 cellular assay), PI3Kα, PI3Kγ and PI3Kδ, respectively.
    PI3K/mTOR Inhibitor-9
  • HY-147306
    ZLc-002 1446971-41-0 98%
    ZLc-002 is a selective inhibitor of nNOS-Capon coupling. ZLc-002 suppresses inflammatory nociception and chemotherapy-induced neuropathic pain. ZLc-002 can be used for the research of anxiety disorder and inflammation.
    ZLc-002
  • HY-147321
    3'-DMTr-dG(iBu) 140839-24-3 98%
    3'-DMTr-dG(iBu) is a nucleoside for the synthesis of nucleic acid, such as antiviral agents used in the research of viral infection (HBV, HDV), and oligonucleotides against Alzheimer’s disease and other tauopathies.
    3'-DMTr-dG(iBu)
  • HY-147331
    Oseltamivir acid methyl ester 208720-71-2 98%
    Oseltamivir acid methyl ester is a precursor form of the neuraminidase inhibitor and antiviral oseltamivir acid. Oseltamivir acid methyl ester is converted to oseltamivir acid by carboxylesterase 1 (CES1).
    Oseltamivir acid methyl ester
  • HY-147333
    Trimipramine N-oxide 14171-70-1 98%
    Trimipramine N-oxide is an active metabolite of the tricyclic antidepressant trimipramine. Trimipramine N-oxide inhibits the human monoamine transporters for noradrenaline (hNAT), serotonin (hSERT), dopamine (hDAT) and the human organic cation transporters (hOCT1 and hOCT2) with IC50s of 11.7, 3.59, 9.4, 9.35 and 27.4 nM, respectively. Trimipramine N-oxide can be used for the research of depression and anxiety.
    Trimipramine N-oxide
  • HY-147352
    NMDA receptor potentiator-1 486427-18-3 98%
    NMDA receptor potentiator-1 (Compound 1368) is a subunit selective NMDA receptor potentiator with IC50s of 4 μM and 5 μM against NR2C and NR2D expression, respectively.
    NMDA receptor potentiator-1
  • HY-147362
    MAO-B-IN-14 1904610-48-5 98%
    MAO-B-IN-14 (Compound 9) is a potent and selective monoamine oxidase-B (MAO-B) inhibitor with an IC50 of 0.95 μM and a Ki of 0.55 μM against human MAO-B.
    MAO-B-IN-14
  • HY-147367
    AM-1488 2079895-60-4 98%
    AM-1488 is a potent, orally active glycine receptor (GlyR) potentiator (hGlyRα3 EC50=0.45 μM).
    AM-1488
Cat. No. Product Name / Synonyms Application Reactivity